Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

NCT01535989 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma Refractory

Interventions

DRUG: Inotuzumab Ozogamicin
DRUG: Temsirolimus

Sponsor

Cristiana Sessa